ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 23

Microvesicle-Associated Hsa-Mir-223-3p Is Elevated in Rheumatoid Synovial Fluid Compared with Osteoarthritis Synovial Fluid

Nancy D. Kim1, Robert B. Lochhead1, Pauline Schmit2, Minna J. Kohler3 and Andrew D. Luster4, 1Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Charlestown, MA, 3Rheumatology, Allergy, and Immunology, Massachusetts General Hospital / Harvard Medical School, Boston, MA, 4Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Microparticles, MicroRNA, osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Microvesicles (MVs) (100-1000 nm diameter) are subcellular particles that are enriched in nucleic acid, including microRNA (miR), which may be transferred from cell to cell as a novel form of intercellular communication.  In this study, we wished to characterize the microRNA content of microvesicles purified from the synovial fluid of patients with osteoarthritis or rheumatoid arthritis.  Furthermore, we wished to determine whether predominant miR species identified in RA SF MVs may be transferred to recipient fibroblast-like synoviocytes (FLS) in vitro.

Methods:

Discarded synovial fluid (SF) from patients with established diagnoses of osteoarthritis (OA) (n=5) or rheumatoid arthritis (RA) (n=5) obtained during routine clinical care was transferred into tubes containing acid-citrate-dextrose and stored at 4°C until further processing.  SF was treated with thromboplastin D, centrifuged at 300 g x 10 minutes and 3000 g x 15 minutes to remove cells and cellular debris, respectively, and filtered through a 0.8 mm filter.  Next, SF was placed into ultracentrifuge tubes diluted with sterile PBS in a 1:8 ratio and ultracentrifuged at 100,000 g x 90 min using a Beckman 70.1Ti rotor.   Purified MV pellets were resuspended in sterile PBS at one-fifth the original volume and quantified using a Nanosight LM10 instrument.  MicroRNA from purified MV pellets was purified using a miRNeasy Serum/Plasma Kit (Qiagen), reverse transcribed, and subject to miRNA analysis using miScript miRNA PCR Serum/Plasma Arrays.  PCR array data were analyzed using the Qiagen GeneGlobe Data Analysis Center online software tool, normalizing to global CT mean of expressed miRNAs, using a cutoff of CT=37.  Purified RA SF MVs were incubated with OA FLS for 16 hours, and pri-miR, pre-miR, and mature miR expression by FLS was determined by qPCR.

Results: Purified RA SF MVs purified in this manner were significantly greater than OA SF MVs (OA vs. RA 24.95 vs. 53.55 million/ml, p=0.0001).  A total of 39 miRs showed greater than 2-fold statistically significant differences in expression between groups (p<0.05).  Of these miRs, hsa-mir-223-3p expression was significantly upregulated in the RA SF MV group (102.4 fold regulation, p=0.005) when compared with the OA SF MV group.  Addition of purified RA SF MVs to cultured human FLS induced expression of mir-223, but not pri-miR-223 or pre-mir-223, indicating that mir-223 in FLS was of exogenous (i.e. microvesicle) origin.

Conclusion: Microvesicle numbers in RA synovial fluid are greater than in OA synovial fluid, consistent with other previously published reports.  We found significantly increased expression of mir-223-3p in RA SF MV, likely reflecting myeloid cell activation in the inflamed joint, and demonstrated that mir-223 may be transferred to recipient FLS in vitro.


Disclosure: N. D. Kim, None; R. B. Lochhead, NIAMS (T32 AR007258-36A1), 2; P. Schmit, None; M. J. Kohler, None; A. D. Luster, None.

To cite this abstract in AMA style:

Kim ND, Lochhead RB, Schmit P, Kohler MJ, Luster AD. Microvesicle-Associated Hsa-Mir-223-3p Is Elevated in Rheumatoid Synovial Fluid Compared with Osteoarthritis Synovial Fluid [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/microvesicle-associated-hsa-mir-223-3p-is-elevated-in-rheumatoid-synovial-fluid-compared-with-osteoarthritis-synovial-fluid/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microvesicle-associated-hsa-mir-223-3p-is-elevated-in-rheumatoid-synovial-fluid-compared-with-osteoarthritis-synovial-fluid/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology